Clinical Trial Search

Phase 3 N=61 Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways

Cystic Fibrosis · Pseudomonas Aeruginosa

Primary: Percentage of Participants Who Discontinued Study Drug Due to Safety or Tolerability Reasons — 0.0 percentage of participants

Gilead Sciences Results May 2014 21.3% serious AE View details

Phase 3 N=66 The Effectiveness of Regular Exercise on Improving Sleep in Older Adults

Sleep Initiation and Maintenance Disorders · Sleep Disorders, Intrinsic

Primary: % Time in Stage 2 Sleep at 12 Months, Adjusted for Baseline — 53.7; 51.0 percentage of sleep time

Stanford University Results May 2014 0.0% serious AE View details

Phase 3 N=13 Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum

Hyperemesis Gravidarum

Primary: PUQE Score for Assessment of Severity in Hyperemesis Gravidarum — 6.3; 8.5 units on a scale — p=0.001

A.O.U. Città della Salute e della Scienza Results Apr 2014 0.0% serious AE View details

Phase 3 N=624 12 / 48 Week Pivotal PFT vs PBO in COPD I

Pulmonary Disease, Chronic Obstructive

Primary: Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks) — -0.007; 0.165; 0.169 Liter — p=<0.0001

Boehringer Ingelheim Results Apr 2014 18.6% serious AE View details

Phase 3 N=1,125 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Brain and Central Nervous System Tumors

Primary: Median Overall Survival Time — 16.6; 14.9 months — p=0.63

Radiation Therapy Oncology Group Results Apr 2014 33.9% serious AE View details

Phase 3 N=455 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

Multiple Myeloma

Primary: Progression-free Survival (PFS) - Primary Analysis — 15.7; 8.0 weeks — p=<0.001

Celgene Results Apr 2014 60.5% serious AE View details

Phase 3 N=934 The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Primary: St. George's Respiratory Questionnaire (SGRQ-C) Total Score After 26 Weeks of Treatment (Non-inferiority Analysis). — 44.70; 45.68; 41.30; 43.19 Score on a scale

Novartis Pharmaceuticals Results Apr 2014 5.8% serious AE View details

Phase 3 N=725 Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit/Hyperactivity Disorder

Primary: Change From Baseline of Period 1 (Baseline 1) to End of Period 1 on Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) Total Score by Treatment…

Novartis Pharmaceuticals Results Apr 2014 1.3% serious AE View details

Phase 3 N=352 A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy

Hallux Valgus

Primary: Sum of Pain Intensity Differences (SPID) Over 48 Hours — 65.3; 131.7; 154.5 Scores on a scale — p=<0.001

Janssen Research & Development, LLC Results Apr 2014 0.6% serious AE View details

Phase 3 N=381 Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)

Type 2 Diabetes Mellitus

Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 24 — -0.76; -0.14 Percent — p=<.001

Merck Sharp & Dohme LLC Results Apr 2014 2.9% serious AE View details

Phase 3 N=1,299 Long-Term Safety Study of TA-7284 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Primary: Safety and Tolerability Assessed by Adverse Events, Hypoglycemic Events — 81.8; 82.8; 14.9; 13.3 percentage of incidences

Tanabe Pharma Corporation Results Apr 2014 4.8% serious AE View details

Phase 3 N=447 Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma

Primary: Percentage of Participants With Complete Response (CR) at End of Treatment Period — 31; 25 percentage of participants

Teva Branded Pharmaceutical Products R&D, Inc. Results Apr 2014 25.0% serious AE View details

Phase 3 N=322 Clinical Trial in Females With Female Pattern Hair Loss

Alopecia

Primary: Target Area Hair Count (TAHC) — 167.3; 169.7; 192.8; 194.4 hairs per centimeter squared — p=0.9170

Johnson & Johnson Healthcare Products Division… Results Apr 2014 3.1% serious AE View details

Phase 3 N=638 Long-Term Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Pain

Chronic Pain

Primary: Mean Change in Average Daily Pain — 0.921 units on a scale

Zogenix, Inc. Results Apr 2014 9.3% serious AE View details

Phase 3 N=60 Subjects' Satisfaction on Pan Facial Aesthetic Enhancement After Treatment With Azzalure® and the Restylane® Range

Aging

Primary: Subject Satisfaction for the Full Face — 92.9; 7.1 percentage of total subjects

Galderma R&D Results Apr 2014 3.3% serious AE View details